Subcutaneous treprostinil was associated with significant early improvements in pulmonary hypertension severity (p<0.001) and right ventricular function in children with group 3 PH.
Observational (n=41)
No
Does subcutaneous treprostinil improve echocardiographic markers of PH severity and RV function in children with group 3 pulmonary hypertension?
Subcutaneous treprostinil is well tolerated and associated with early improvements in echocardiographic markers of PH severity and RV function in children with group 3 pulmonary hypertension.
p-value: p=<0.001
ABSTRACT Use of subcutaneous treprostinil (TRE) in children with pulmonary hypertension (PH) secondary to lung disease (group 3 PH) is not well described. We hypothesized that initiation of TRE is associated with improvement in PH severity and right ventricular (RV) function with minimal early side effects. We conducted a single‐center retrospective analysis of children with group 3 PH treated with TRE between 2006 and 2022. We compared echocardiographic changes in PH severity and RV systolic function over the first 3‐6 months of TRE and described adverse effects over the first 48 h of therapy. Forty‐one patients (56% male), aged 6 days to 15 years old at the time of TRE initiation, were included. The most common associated diagnoses were bronchopulmonary dysplasia (63%), congenital diaphragmatic hernia (10%), and pulmonary hypoplasia (10%). TRE was associated with improvement in PH severity ( p < 0.001), estimated by interventricular septal position at end‐systole ( p = 0.001), RV systolic pressure to systemic blood pressure ratio ( p < 0.001), and flow direction across a simple shunt ( p = 0.153). There were improvements in individual markers of RV function including tricuspid annular plane systolic excursion ( p = 0.005), tricuspid annulus dilation ( p = 0.004), RV global longitudinal strain ( p < 0.001), RV free wall longitudinal strain ( p < 0.001), and qualitative RV systolic function ( p = 0.002). Over the first 48 h of TRE, the dose was reduced in 3 patients (7%) due to hypotension, hypoxemia, or emesis, all of whom tolerated re‐escalation within 48 h. TRE is well tolerated and is associated with early improvement in PH severity and RV function in children with group 3 PH.
Parvathaneni et al. (Wed,) conducted a observational in Group 3 pulmonary hypertension (n=41). Subcutaneous treprostinil was evaluated on Echocardiographic changes in pulmonary hypertension severity (p=<0.001). Subcutaneous treprostinil was associated with significant early improvements in pulmonary hypertension severity (p<0.001) and right ventricular function in children with group 3 PH.